A therapy mixture of Braftovi (encorafenib), Erbitux (cetuximab) and chemotherapy confirmed promising anti-tumor exercise in sufferers with BRAF V600E-mutant metastatic colorectal most cancers who had been beforehand handled with a minimum of one line of systemic remedy, based on a presentation on the 2024 ESMO Congress.
A presentation on the convention highlighted up to date security outcomes from the section 3 BREAKWATER examine, which included three parts: a security portion, a section 3 randomization and a second randomization labeled as cohort 3.
The security portion included two cohorts: Braftovi plus Erbitux and FOLFIRI chemotherapy (cohort 1); and Braftovi plus Erbitux and mFOLFOX6 chemotherapy (cohort 2). The section 3 part randomized sufferers to 3 therapy teams: Erbitux alone; Erbitux plus mFOLFOX6 chemotherapy; or the management group of three chemotherapy regimens: FOLFIRI, mFOLFOX6, or capecitabine and oxaliplatin (CAPOX) with or with out Avastin (bevacizumab). Cohort 3 randomly assigned sufferers to both Erbitux/FOLFIRI chemotherapy or FOLFIRI chemotherapy with or with out Avastin.
Research Highlights:
- A therapy mixture of Braftovi, Erbitux and chemotherapy confirmed promising anti-tumor exercise in sufferers with BRAF V600E-mutant metastatic colorectal most cancers.
- Amongst beforehand handled sufferers receiving Braftovi, Erbitux and chemotherapy as a second-line remedy, the ORR was 44.4%.
- In sufferers receiving Braftovi, Erbitux and chemotherapy as a second-line remedy, the median DOR was 12.5 months, the median PFS was 12.6 months, and the median OS was 19.7 months.
- Sufferers should have confirmed stage 4 colorectal most cancers and be ineligible if they’ve tumors which might be microsatellite instability-high or mismatch repair-deficient.
Of observe, the presentation of the BREAKWATER examine at ESMO primarily targeted on the security portion, which included sufferers from cohort 1.
There have been 30 sufferers enrolled in cohort 1. The median age was 56.5 years and 66.7% had been males. The ECOG efficiency standing was both 0 (potential to independently carry out each day duties; 73.3%) or 1 (potential to carry out most each day duties independently; 26.7%). Twelve sufferers had not acquired prior remedy, and 18 sufferers had one prior line of remedy.
In a presentation on the 2024 ESMO Congress, Dr. Josep Tabernero, head of the Division of Medical Oncology, Vall d’Hebron College Hospital and director of the Vall d’Hebron Institute of Oncology in Barcelona, Spain, mentioned findings from the trial. Tabernero reported that just one dose-limiting toxicity (DLT; unwanted effects from medication that forestall a rise in dose) occurred with the Erbitux/chemotherapy mixture, which was grade 4 (life-threatening) neutropenia (decrease ranges of a white blood cell sort) that lasted greater than seven days.
Remedy-related unwanted effects of any grade had been skilled by 93.3% of sufferers, with 50% of sufferers experiencing grade 3 (extreme)/4 treatment-related unwanted effects, and 16.7% of sufferers experiencing a critical aspect impact associated to check therapy. There have been no deaths associated to the examine therapy.
Efficacy information confirmed an goal response fee (ORR; proportion of sufferers whose most cancers shrunk or disappeared) of 83.3% in sufferers from cohort 1 receiving Braftovi, Erbitux plus chemotherapy within the first-line metastatic setting. There have been two full responses (CRs; disappearance of most cancers), eight partial responses (PRs; most cancers shrunk) and one affected person with steady illness (SD; most cancers didn’t enhance or worsen). The median period of response (DOR) was not estimable. The median progression-free survival (PFS; time sufferers are alive with out their illness worsening) was not evaluable, which means not sufficient sufferers had their illness worsened by the information assortment date, and the median total survival (OS; time sufferers dwell no matter illness standing) was not evaluable.
Amongst beforehand handled sufferers from cohort 1 receiving therapy as a second-line remedy, the ORR was 44.4%. There was one CR, seven PRs and 7 sufferers with SD. The median DOR was 12.5 months. The median PFS was 12.6 months, and the median OS was 19.7 months.
“The mixture of [Braftovi, Erbitux] plus chemotherapy was tolerable with out new security alerts in sufferers with BRAF V600E-mutant metastatic colorectal most cancers … [and] confirmed promising enchancment in key efficacy measures,” stated Tabernero.
The BREAKWATER trial assessed the mix of Braftovi and Erbitux with or with out chemotherapy in sufferers with metastatic colorectal most cancers. Sufferers should have confirmed stage 4 colorectal most cancers harboring a BRAF V600E mutation. Sufferers had been ineligible if they’d tumors which might be microsatellite instability-high or mismatch repair-deficient.
Security Amongst Sufferers With Metastatic Colorectal Most cancers
On the 2024 ESMO Congress, Tabernero shared information from cohort 1 of the security portion, which evaluated the mix of Braftovi, Erbitux and chemotherapy. The first aim of the security portion of the trial was DLTs, with secondary objectives together with security and antitumor exercise.
Extra security information confirmed that each one sufferers skilled treatment-emergent unwanted effects, with 63.3% and 46.7% experiencing grade 3/4 treatment-emergent unwanted effects and critical treatment-emergent unwanted effects, respectively. Remedy-emergent unwanted effects resulting in dose discount, dose interruption or everlasting discontinuation of any drug occurred in 53.3%, 73.3% and 30% of sufferers, respectively. Remedy-emergent unwanted effects had been related to two affected person deaths.
Remedy-emergent unwanted effects throughout all grades occurring in a minimum of 30% of sufferers included nausea (50%), diarrhea (46.7%), constipation (43.3%), fatigue (43.3%), dermatitis acneiform (acne-like bumps; 40%), rash (33.3%) and pores and skin hyperpigmentation (30%). Remedy-emergent unwanted effects of grade 3 or worse included two circumstances of dermatitis acneiform and one case every of diarrhea, constipation and fatigue.
The Erbitux mixture is at present permitted by the FDA to be used in sufferers beforehand handled for BRAF V600E-mutated metastatic colorectal most cancers.
“At the moment, there are not any particularly focused first-line therapies for BRAF V600E-mutant metastatic colorectal most cancers, which highlights the unmet want for novel therapy choices for this affected person inhabitants,” stated Tabernero.
In his concluding remarks, Tabernero stated, “These outcomes assist the continued analysis of Erbitux plus chemotherapy as a therapy choice for sufferers with BRAF V600E-mutated metastatic colorectal most cancers in cohort 3 of the BREAKWATER examine.”
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
